How should ruxolitinib cream (Opzelura) be used properly?

Ruxolitinib cream (trade name: Opzelura) is a topical JAK inhibitor mainly used to treat non-segmental vitiligo and mild to moderate atopic dermatitis. The drug modulates the immune response and improves skin inflammation and depigmentation by inhibiting the JAK1 and JAK2 pathways. To ensure efficacy and safety, patients should follow standardized medication instructions when using ruxolitinib cream.

You should fully understand the indications and contraindications before use. Ruxolitinib cream is suitable for patients aged 12 years and above. The type of skin lesions should be clearly identified before use to avoid misuse in infectious, ulcerative or severe skin damage areas. If there is a skin infection in the affected area, the infection should be controlled before using this product. In addition, patients with severe immune system diseases or long-term use of immunosuppressants should be used with caution under the guidance of a doctor.

Medication methods need to be strictly regulated. It is generally recommended to use it once a day in the morning and evening. Apply an appropriate amount of cream evenly to the affected area and massage gently to help absorption. Avoid applying ointment to normal skin, eyes, oral and nasal mucosa, or damaged skin areas. Wash your hands promptly after taking medication to avoid adverse reactions caused by drug residues. If obvious irritation, itching or redness occurs during continued use, you should suspend use and seek medical treatment in time.

You should follow the doctor’s recommendations for efficacy evaluation and medication adjustments. The treatment course of ruxolitinib cream for treating vitiligo is usually longer. It usually starts to show effect after 8 weeks of use, but it takes several months of continuous use to see obvious pigment recovery. During the treatment process, the doctor will adjust the frequency of medication or whether to combine it with other therapies based on the disease response. Patients should not stop taking the medication without authorization or increase the frequency of medication on their own to avoid side effects or reduced efficacy. Long-term users should also be followed up regularly to monitor for signs of infection risks or other systemic adverse reactions.

Reference materials:https://www.opzelura.com/